针对癌症治疗的 PI3K 通路。
Targeting the PI3K pathway for cancer therapy.
机构信息
Division of Hematology & Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
出版信息
Future Med Chem. 2012 Jun;4(9):1153-69. doi: 10.4155/fmc.12.56.
Abstract
The PI3K pathway plays an important role in key cellular functions such as cell growth, proliferation and survival. Genetic and epigenetic alterations in different pathway components lead to aberrant pathway activation and have been observed in high frequencies in various tumor types. Consequently, significant effort has been made to develop antineoplastic agents targeting different nodes in this pathway. Additionally, PI3K pathway status may have predictive and prognostic implications, and may contribute to drug resistance in tumor cells. This article provides an overview of our current knowledge of the PI3K pathway with an emphasis on its application in cancer treatment.
摘要
PI3K 通路在细胞的重要功能中发挥着重要作用，如细胞生长、增殖和存活。不同通路成分的遗传和表观遗传改变导致异常通路激活，并在各种肿瘤类型中高频观察到。因此，人们做出了巨大努力来开发针对该通路不同节点的抗肿瘤药物。此外，PI3K 通路状态可能具有预测和预后意义，并可能导致肿瘤细胞的耐药性。本文概述了我们目前对 PI3K 通路的认识，重点介绍其在癌症治疗中的应用。
相似文献
1
Targeting the PI3K pathway for cancer therapy.针对癌症治疗的 PI3K 通路。
Future Med Chem. 2012 Jun;4(9):1153-69. doi: 10.4155/fmc.12.56.
2
Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers.各种癌症中的磷酸肌醇-3-蛋白激酶（PI3K）途径的分子靶向治疗。
Int J Mol Sci. 2024 Feb 6;25(4):1973. doi: 10.3390/ijms25041973.
3
The PI3K pathway as drug target in human cancer.PI3K 通路作为人类癌症的药物靶点。
J Clin Oncol. 2010 Feb 20;28(6):1075-83. doi: 10.1200/JCO.2009.25.3641. Epub 2010 Jan 19.
4
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer.PI3K 信号通路中的受体酪氨酸激酶：癌症治疗靶点。
Semin Cancer Biol. 2019 Dec;59:3-22. doi: 10.1016/j.semcancer.2019.03.006. Epub 2019 Mar 31.
5
Targeting PI3K/Akt signal transduction for cancer therapy.针对 PI3K/Akt 信号转导通路的癌症治疗策略。
Signal Transduct Target Ther. 2021 Dec 16;6(1):425. doi: 10.1038/s41392-021-00828-5.
6
Status of PI3K inhibition and biomarker development in cancer therapeutics.PI3K 抑制在癌症治疗中的现状和生物标志物的开发。
Ann Oncol. 2010 Apr;21(4):683-691. doi: 10.1093/annonc/mdp347. Epub 2009 Aug 27.
7
Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.磷脂酰肌醇 3-激酶抑制在慢性淋巴细胞白血病中的作用。
Hematol Oncol Clin North Am. 2013 Apr;27(2):329-39. doi: 10.1016/j.hoc.2012.12.002.
8
Targeting the PI3K signaling pathway in cancer therapy.针对癌症治疗中的 PI3K 信号通路。
Expert Opin Ther Targets. 2012 Jan;16(1):121-30. doi: 10.1517/14728222.2011.644788. Epub 2012 Jan 12.
9
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.针对血液系统恶性肿瘤患儿的 PI3K/AKT/mTOR 信号通路。
Paediatr Drugs. 2012 Oct 1;14(5):299-316. doi: 10.2165/11594740-000000000-00000.
10
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.GDC-0980 是一种新型的 I 类 PI3K/mTOR 激酶抑制剂，在由 PI3K 通路驱动的癌症模型中具有强大的活性。
Mol Cancer Ther. 2011 Dec;10(12):2426-36. doi: 10.1158/1535-7163.MCT-11-0446. Epub 2011 Oct 13.
引用本文的文献
1
The Role of RAC2 and PTTG1 in Cancer Biology.RAC2和PTTG1在癌症生物学中的作用。
Cells. 2025 Feb 23;14(5):330. doi: 10.3390/cells14050330.
2
Insilco and Invitro approaches identify novel dual PI3K/AKT pathway inhibitors to control acute myeloid leukemia cell proliferations.计算机模拟和体外实验方法鉴定出新型双PI3K/AKT通路抑制剂以控制急性髓系白血病细胞增殖。
Med Oncol. 2022 Oct 8;39(12):249. doi: 10.1007/s12032-022-01846-1.
3
Mechanisms of Natural Extracts of That Target Lipid-Dependent Cancer Pathways: A View from the Signaling Pathway.天然提取物靶向脂质依赖性癌症途径的机制：从信号通路角度的观察。
Int J Mol Sci. 2022 May 26;23(11):5972. doi: 10.3390/ijms23115972.
4
Genetic Polymorphisms in microRNA Genes Targeting PI3K/Akt Signal Pathway Modulate Cervical Cancer Susceptibility in a Chinese Population.靶向PI3K/Akt信号通路的微小RNA基因中的遗传多态性调节中国人群宫颈癌易感性。
Front Genet. 2022 Apr 14;13:856505. doi: 10.3389/fgene.2022.856505. eCollection 2022.
5
The Expression of Signaling Genes in Breast Cancer Cells.信号基因在乳腺癌细胞中的表达
Biology (Basel). 2022 Apr 3;11(4):555. doi: 10.3390/biology11040555.
6
A doxorubicin-platinum conjugate system: impacts on PI3K/AKT actuation and apoptosis in breast cancer cells.一种阿霉素-铂共轭体系：对乳腺癌细胞中PI3K/AKT激活及细胞凋亡的影响
RSC Adv. 2021 Jan 25;11(8):4818-4828. doi: 10.1039/d0ra06708c. eCollection 2021 Jan 21.
7
Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway.突变型 p53 通过促进肿瘤生长和免疫逃逸的 PH LPP2/AKT/PD-L1 通路实现功能获得。
Int J Biol Sci. 2022 Mar 14;18(6):2419-2438. doi: 10.7150/ijbs.67200. eCollection 2022.
8
The biochemical and clinical implications of phosphatase and tensin homolog deleted on chromosome ten in different cancers.10号染色体缺失的磷酸酶和张力蛋白同源物在不同癌症中的生化及临床意义
Am J Cancer Res. 2021 Dec 15;11(12):5833-5855. eCollection 2021.
9
Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer.细胞穿透肽修饰的载雷帕霉素靶蛋白复合物 siRNA 的石墨烯氧化物纳米粒子治疗三阴性乳腺癌。
Drug Des Devel Ther. 2021 Dec 10;15:4961-4972. doi: 10.2147/DDDT.S330059. eCollection 2021.
10
Pathway-extended gene expression signatures integrate novel biomarkers that improve predictions of patient responses to kinase inhibitors.通路扩展基因表达特征整合了新型生物标志物，可改善对患者激酶抑制剂反应的预测。
MedComm (2020). 2020 Dec 10;1(3):311-327. doi: 10.1002/mco2.46. eCollection 2020 Dec.
本文引用的文献
1
Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma.AKT 通路的阻断抑制了头颈部鳞状细胞癌原位模型中的转移。
Laryngoscope. 2011 Nov;121(11):2359-65. doi: 10.1002/lary.22180.
2
p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors.p37δ 是一种新型的 PI3K p110δ 同工型，它可促进细胞增殖，并在肿瘤中过度表达。
Oncogene. 2012 Jul 5;31(27):3277-86. doi: 10.1038/onc.2011.492. Epub 2011 Oct 24.
3
PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.PIK3CA 激酶结构域突变鉴定出具有不良预后的 III 期结肠癌患者亚组。
Cell Oncol (Dordr). 2011 Dec;34(6):523-31. doi: 10.1007/s13402-011-0054-4. Epub 2011 Aug 10.
4
Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.瑞戈非尼：软组织肉瘤和其他恶性肿瘤治疗中的有前途的药物。
Future Oncol. 2011 Jul;7(7):827-39. doi: 10.2217/fon.11.57.
5
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.PI3K 通路激活导致曲妥珠单抗和拉帕替尼的疗效均降低。
BMC Cancer. 2011 Jun 15;11:248. doi: 10.1186/1471-2407-11-248.
6
Molecular mechanism of HIF-1-independent VEGF expression in a hepatocellular carcinoma cell line.缺氧诱导因子-1 独立的血管内皮生长因子表达的分子机制在肝癌细胞系中的研究。
Int J Mol Med. 2011 Sep;28(3):449-54. doi: 10.3892/ijmm.2011.719. Epub 2011 Jun 8.
7
Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification.NOTCH 和 AKT 信号在小鼠巨核细胞谱系特化过程中的串扰。
Blood. 2011 Aug 4;118(5):1264-73. doi: 10.1182/blood-2011-01-328567. Epub 2011 Jun 7.
8
INPP4B: the new kid on the PI3K block.INPP4B：磷脂酰肌醇-3激酶领域的新成员。
Oncotarget. 2011 Apr;2(4):321-8. doi: 10.18632/oncotarget.260.
9
PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.PIK3R1（p85α）在原发性子宫内膜癌中高频体细胞突变。
Cancer Res. 2011 Jun 15;71(12):4061-7. doi: 10.1158/0008-5472.CAN-11-0549. Epub 2011 Apr 8.
10
mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.mTORC1 和 mTORC2 通过 RhoA 和 Rac1 信号通路调节结直肠癌的 EMT、迁移和转移。
Cancer Res. 2011 May 1;71(9):3246-56. doi: 10.1158/0008-5472.CAN-10-4058. Epub 2011 Mar 23.
Zotero 插件